Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.
Samer S AlMasriMazen S ZenatiAnnissa DesilvaIbrahim NassourBrian A BooneAatur D SinghiDavid L BartlettLance A LiottaVirginia EspinaPatricia LoughranMichael T LotzeAlessandro PanicciaHerbert J ZehAmer H ZureikatNathan BaharyPublished in: Cancer medicine (2021)
Compared to historical data, neoadjuvant autophagy inhibition with HCQ plus gemcitabine is associated with encouraging long-term survival for patients with PDAC.